Oncology Fellows
Vol.18-No.2
Volume: 18
Issue: 2
Vol.18-No.1
Volume: 18
Issue: 1
Vol. 17/No. 3
Vol.17/No.4
Volume: 17
Issue: 4
Vol. 17/No. 2
Volume: 17
Issue: 2
Vol. 17/No. 1
Volume: 17
Issue: 1
Vol. 16/No. 4
Volume: 16
Issue: 4
Vol. 16/No. 3
Volume: 16
Issue: 3
Vol. 16/No. 2
Volume: 16
Issue: 2
Vol. 16/No. 1
Volume: 16
Issue: 1
Vol. 15/No. 4
Volume: 15
Issue: 4
Vol. 15/No. 3
Volume: 15
Vol. 15/No. 2
Volume: 14
Vol. 15/No. 1
Volume: 15
Issue: 1
Vol. 14/No. 4
Volume: 14
Issue: 4
Vol. 14/No. 3
Volume: 14
Issue: 3
Vol. 14/No. 2
Volume: 14
Issue: 2
Vol. 14/No. 1
Volume: 14
Issue: 1
Vol. 13/No. 4
Volume: 13
Issue: 4
Vol. 13/No. 3
Volume: 13
Issue: 3
Vol. 13/No. 2
Volume: 13
Issue: 2
Vol. 13/No. 1
Volume: 13
Issue: 1
December 2020
Volume: 12
Issue: 4
September 2020
Volume: 1
Issue: 1
June 2020
Volume: 12
Issue: 2
March 2020
Volume: 12
Issue: 1
December 2019
Volume: 11
Issue: 3
September 2019
Volume: 11
Issue: 3
March 2019
Volume: 11
Issue: 1
June 2019
Volume: 11
Issue: 2
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
Improved Outcomes for High-Risk CLL Remain Key Focus for Continued Development of Fixed-Duration Regimens
3
Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC
4
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
5